The inadequacy of the present medical therapy of Pseudomonas aeruginosa endocarditis prompted an investigation of the in vitro activities of aztreonam, cefsulodin, and imipenem compared with that of ticarcillin against 37 strains of P. aeruginosa isolated from patients with endocarditis. Inhibitory and bactericidal activities were studied for each I-lactam alone and in combination with tobramycin. All agents showed excellent inhibitory activity. Imipenem was the most inhibitory P-lactam yet lacked inhibitory synergy against 95% of the strains and bactericidal synergy against 62%. Tolerance to imipenem was seen in six strains. Aztreonam alone was bactericidal against 46% of the strains (at 16 ,ug/ml) and showed bactericidal synergy in 70%. Cefsulodin alone was even less active but similar to aztreonam synergistically. Ticarcillin and tobramycin inhibited all strains as single agents and showed universal bactericidal synergy in combination. None of the new I-lactams showed consistent superiority to the presently used agent, ticarcillin.
lactams of the cephalosporin, monobactam, and carbapenem classes have considerable inhibitory activity against P. aeruginosa in vitro. However, there is little information available concerning their bactericidal and synergistic activities in combination with an aminoglycoside. Both of these properties are important in determining whether these agents may offer an advantage over current therapy or at least an equipotent alternative in penicillin-allergic patients with P. aeruginosa endocarditis.
We therefore investigated the inhibitory and bactericidal activities of aztreonam, cefsulodin, and imipenem alone and in combination with tobramycin against 37 strains of P. aeruginosa isolated from patients with P. aeruginosa endocarditis to determine whether they compared favorably in vitro with the present therapeutic regimen of ticarcillin and tobramycin.
MATERIALS AND METHODS
Organisms and patients. Strains of P. aeruginosa were isolated from blood or excised cardiac valves of patients with a diagnosis of P. aeruginosa endocarditis seen at the University of Illinois Hospitals from 1979 through 1983. Diagnostic criteria for P. aeruginosa endocarditis included persistent P. aeruginosa bacteremia and absence of an obvious source other than the heart (17). All patients were intravenous drug users. Duplicate isolates from the same patient were excluded unless they differed in serotype (three instances). The isolates were identified by standard criteria (8) .
Serotyping. Serotyping was performed by slide agglutination with live P. aeruginosa organisms picked from blood agar plates with antisera against the 17 0 antigens of the International Antigenic Typing Scheme (3). Antisera were obtained from Difco Laboratories (Detroit, Mich. Susceptibility testing. MICs of the five antibiotics were determined for each organism in microtiter wells with serial twofold dilutions of each drug in 0.025 ml of Mueller-Hinton broth (lot #713936; Difco) supplemented with MgCl2 and CaCl2 to achieve final calcium and magnesium concentrations of 5.9 ± 0.2 and 3.1 ± 0.2 mg per 100 ml, respectively, as determined by an automatic clinical analyzer (Du Pont Instruments, Wilmington, Del.). Overnight growth of each strain was diluted in the broth and then added in 0.25-ml portions to each antibiotic dilution to achieve an initial inoculum of approximately 106 organisms per ml. The wells were sealed with adhesive cellophane, gently agitated, and then incubated at 37°C. The MIC was defined as the lowest concentration at which no turbidity was visible after 18 to 24 h of incubation.
MBCs were determined by sterile puncture of the cellophane over all the wells lacking turbidity and aspiration of the entire contents (0.05 ml). To reduce antibiotic carry-over (18) , the well contents were spot inoculated onto blood agar and allowed to dry, followed by streaking the entire agar surface with a sterile wire. The plates were incubated for 18 to 24 h at 37°C. The number of visible colonies was counted, and the MBC was defined as the lowest concentration at which 99.9% of the colonies were killed (10 colonies or fewer remaining).
Susceptibility breakpoints were based on achievable concentrations in serum (11, 19) and suggestions from the research divisions of the supplying pharmaceutical companies.
Tolerance was defined as an MBC/MIC ratio of -32. Synergy testing. Synergy was evaluated for each of the four ,-lactams combined with tobramycin against each strain with serial twofold dilutions in microtiter wells. Inocula, prepared as described above, were added to supplemented ANTIMICROB. AGENTS CHEMOTHER. Bactericidal synergy was common with all the ,-lactams except imipenem, which in combination with tobramycin showed synergy for less than 50% of the strains. All strains showed bactericidal synergy with the tobramycin-ticarcillin combination. Antagonism was not observed with any of the agents tested.
Serotyping. All 37 strains were typable, and 33 (89%) were serotype 11. Only two other serotypes were represented: three strains were type 1, and one strain was type 4.
DISCUSSION
The combination of ticarcillin and tobramycin is the recommended antimicrobial therapy for patients with P. aeruginosa endocarditis (16) . More than 80% of patients with right-sided disease can be cured with this combination, but the outcome for left-sided involvement remains poor (16) . In this study, we defined the in vitro inhibitory, bactericidal, and synergistic activities of drugs from three 3-lactam classes against strains of P. aeruginosa isolated from patients with P. aeruginosa endocarditis to determine whether any of these agents compared favorably with ticarcillin.
The vast majority of our strains (89%) were serotype 11. This serotype has been reported to be the most common cause of single-strain P. aeruginosa outbreaks (6) and bacteremias (4) at other institutions.
Imipenem, a carbapenem with one of the broadest antimicrobial spectra available (12) , was the most active P-lactam tested when MICs were used for comparisons. However, bactericidal activity with imipenem occurred over a wide range of concentrations, and tolerance was seen in 16% of the strains. Similar observations have been made with this agent against endocarditis-causing strains of enterococci; inhibitory activity looks promising but killing activity does not (2) . In vitro tolerance of P. aeruginosa to P-lactam antibiotics may be due to the ability of the organism to remain viable on the vessel surface, where antibiotic con- centrations are not bactericidal (7, 10) . This can be prevented by vigorous agitation (7), but such agitation may cause cross-contamination of the microtiter wells and invalidate results (18) . The clinical significance of ,B-lactam tolerance is unclear, but it correlates with increased morbidity in intravenous drug users with Staphylococcus aureus endocarditis (14) . We also found that bactericidal synergy between imipenem and tobramycin was absent in almost two-thirds of the strains. The lack of synergy raises some doubts as to the potential in vivo efficacy of imipenem for P. aeruginosa endocarditis since it has been suggested that synergy is a necessary, although not sufficient, prerequisite for cure (15) . Aztreonam is the first investigationally available monobactam. It has an antimicrobial spectrum similar to that of gentamicin, including inhibitory activity against many strains of P. aeruginosa (9) . It appears to share little cross-immunogenicity with other P-lactams (1) and thus, if shown to be effective, would be a useful alternative to ticarcillin in penicillin-allergic patients with P. aeruginosa endocarditis. Only two (6%) of our strains were resistant to aztreonam, and bactericidal activity was observed in about half of the strains at 16 ±ug/ml. Synergy at the MIC was seen in only one-quarter of the strains but at the MBC was present in almost three-quarters. On the basis of these in vitro findings, one could speculate that in a patient in whom allergic cross-reactivity with penicillins is a concern, aztreonam may be a useful alternative to ticarcillin against many of the strains of P. aeruginosa that cause endocarditis.
Cefsulodin is a narrow-spectrum antipseudomonal cephalosporin (13) that has undergone extensive clinical trials and will soon receive approval from the Food and Drug Administration. All but three (8%) of our strains were susceptible by MIC determination, but bactericidal activity was limited, with only 19% of the strains killed at 16 p.g/ml.
This concentration is above that demonstrable in heart valves (5), and vegetation penetration may be even worse. Synergy results with cefsulodin-tobramycin were similar to those with aztreonam-tobramycin.
All our P. aeruginosa strains that cause endocarditis were susceptible to ticarcillin at a breakpoint of 64 ,ug/ml. Inhibitory synergy occurred most often with the ticarcillin-tobramycin combination, and bactericidal synergy was universal. On the basis of such findings, we conclude that the other P-lactams studied showed no in vitro antimicrobial advantage over ticarcillin in the treatment of P. aeruginosa endocarditis. None of the ,-lactams showed sufficient bactericidal activity at achievable levels to warrant their consideration as single-drug therapy.
We did not assay the activity of new antipseudomonal penicillins against our strains. Reyes and Lerner have reported that the azlocillin-aminoglycoside combination is consistently synergistic against their P. aeruginosa strains that cause endocarditis but that therapeutic results are disappointing when piperacillin is substituted for ticarcillin in vivo (16) . Other ,B-lactams with antipseudomonal activity should also be studied with similar methods and time-kill curves. All such in vitro work awaits confirmation by appropriately controlled human clinical trials.
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